No black box warning on record for Danyelza

As of the latest FDA labeling reviewed, Danyelza (NAXITAMAB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Danyelza medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Neurotoxicity: Peripheral neuropathy, neurological disorders of the eye, and prolonged urinary retention have also occurred. Permanently discontinue as recommended. ( 2.3 , 5.2 ) Myocarditis: Withhold, reduce dose, or discontinue based on severity. ( 2.3 , 5.3 ) Hypertension: Monitor blood pressure during and after infusion as recommended. Withhold, reduce infusion rate,

No black box warning on record for Danyelza

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Neurotoxicity: Peripheral neuropathy, neurological disorders of the eye, and prolonged urinary retention have also occurred. Permanently discontinue as recommended. ( 2.3 , 5.2 ) Myocarditis: Withhold, reduce dose, or discontinue based on severity. ( 2.3 , 5.3 ) Hypertension: Monitor blood pressure during and after infusion as recommended. Withhold, reduce infusion rate,

Danyelza Black Box Warning

No black box warning on record for Danyelza

Other warnings & precautions

Danyelza Black Box Warning

No black box warning on record for Danyelza

Other warnings & precautions